We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urine Assay Encourages Men to Undergo Painless Chlamydia Test

By LabMedica International staff writers
Posted on 31 Jul 2009
Print article
A new urine test will allow doctors to diagnose the sexually transmitted Chlamydia infection in men within an hour, improving the ability to successfully treat the infection on the spot and prevent retransmission.

The Chlamydia Rapid Test can be used with minimal training. It was designed to be used in conjunction with FirstBurst, a device for collecting the first voided urine from men, which collects six times the amount of Chlamydia bacteria compared to a standard urine sample.

Dr. Helen Lee, associate professor and reader in medical biotechnology at the University of Cambridge (Cambridge, UK), and colleagues developed the Chlamydia test. To commercialize the technologies developed at Cambridge, Dr. Lee founded the company, Diagnostics for the Real World Ltd. (DRW; Sunnyvale, CA, USA).

The team developed the Chlamydia Rapid Test on the signal-amplified system (SAS) for protein targets. It is based on multiplying a visual signal via an increase in the valence and size of the colored immune complex, by chemically coupling multiple copies of a hapten to the primary detection antibodies. The resulting lattice formed between the analyte, multiple hapten-labeled antibodies, and the antihapten color conjugate yields a strong visual signal.

Once diagnosed, chlamydia can be treated easily with a one-off antibiotic pill. However, until now, male rapid tests for chlamydia have been relatively inaccurate and involved urethral swabs, which can cause discomfort.

"Horror stories about painful swabs have put men off getting tested for chlamydia, and other noninvasive tests are expensive, technically complex, and take days to obtain the result," explained Dr Helen Lee. "This has led to many cases of infection in men going undiagnosed and being transmitted to their female partners, with potentially more serious complications."

In the majority of cases, the infection is asymptomatic in both men and women. If symptoms show in men, they may include discharge or pain when passing urine. It has been suggested that, if untreated, even when there are no observable symptoms, chlamydia may be a cause of reduced fertility. In women, the bacteria can lead to serious complications, such as pelvic inflammatory disease, chronic pelvic pain, and ectopic pregnancy.

In 2008, young people accounted for two-thirds of all new episodes of uncomplicated Chlamydia infection diagnosed in genitourinary medicine clinics. In England, as many 68 young men in every 1000 carry the infection, the figure is nearly 84 out of 1000 for young women. Since the mid-1990s, the number of diagnosed infections has risen by an average of 7500 per year to over 123,000.

A study describing the successful evaluation of the new Chlamydia test was published in the July 28, 2009 edition of the BMJ. The authors concluded, "The test could also provide a simple and reliable alternative to nucleic acid amplification assays for testing of male urine in chlamydial screening programs in high prevalence settings."

Related Links:

University of Cambridge


New
Gold Member
ANCA IFA
Kallestad Autoimmune ANCA IFA Complete Kit
Unit-Dose Packaging solution
HLX
New
Clostridium Difficile Assay
Revogene C. Difficile
New
Automated Nucleic Acid Extraction Instrument
EX9600

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The CELLSEARCH System is the first and only clinically validated, FDA-cleared system for identification, isolation, and enumeration of CTCs from a simple blood test (Photo courtesy of Menarini, Inc.)

Early Blood Test Predicts Survival in Patients with Metastatic Prostate Cancer

Before prostate cancer spreads, it can be effectively treated with surgery or radiation. However, once the cancer metastasizes and becomes incurable, systemic treatments are used to extend survival as... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.